Used in immunotherapy research and vaccine development, particularly in targeting cancers that express CLDN6, such as testicular, ovarian, and lung cancers. Acts as a highly immunogenic platform to elicit strong immune responses due to its virus-like particle structure, making it valuable in cancer vaccine studies. Enables the presentation of CLDN6 antigen in a repetitive, non-infectious form that enhances B cell activation and antibody production. Investigated for use in personalized cancer vaccines and as a tool for evaluating anti-CLDN6 antibody efficacy in preclinical models.